In Q4 2025, Novartis posted marginally lower net sales and a decline in net income year over year, reflecting US generic erosion and pricing pressures, partially offset by strong growth from priority brands.

Novartis delivered strong Q3 2025 results, driven by key brands like Kisqali and Kesimpta, along with continued innovation success including the FDA approval of Rhapsido.

Novartis delivered a robust Q2 2025 with $14.05 billion in revenue, driven by strong sales from Kisqali, Pluvicto, and Scemblix. Net income rose to $4.02 billion, and free cash flow increased significantly. The company raised its FY25 core operating income guidance.